BOMAC SCOURBAN PLUS
ChemWatch Material Safety Data Sheet CHEMWATCH 4632-24
Issue Date: Fri 22-Apr-2005 CD 2005/2 Page 1 of 16
Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION
PRODUCT NAME
BOMAC SCOURBAN PLUS
SYNONYMS
Product Code: 3622
! 09/01
oral treatment
PRODUCT USE
For animal treatment only. For the prevention and treatment of intestinal
infections in horses, cattle, goats, pigs, sheep, dogs and cats. Oral use only.
SUPPLIER
Company: Bomac Laboratories Ltd
Address:
Cnr. Wiri Station Rd & Hobill Avenue
Manukau City
Auckland,
NZL
Telephone: +64 9 262 3169
Fax: +64 9 262 3008
Section 2 - HAZARDS IDENTIFICATION
STATEMENT OF HAZARDOUS NATURE
NON-HAZARDOUS SUBSTANCE. NON-DANGEROUS GOODS. According to
the Criteria of NOHSC, and the ADG Code.
POISONS SCHEDULE
None
RISK
SAFETY
Avoid exposure - obtain special instructions before use.
Take off immediately all contaminated clothing.
In case of contact with eyes, rinse with plenty of water and contact Doctor or
Poisons Information Centre.
If you feel unwell contact Doctor or Poisons Information Centre. (Show the label
if possible).
Section 3 - COMPOSITION / INFORMATION ON INGREDIENTS
NAME CAS RN %
sulfamethazine 57-68-1 31
kaolin 1332-58-7 10.33
sulfaguanidine 57-67-0 2.13
sulfadiazine 68-35-9 2.84
sodium chloride 7647-14-5 1.13
streptomycin sulfate 3810-74-0 0.76
neomycin sulfate 1405-10-3 0.18
hyoscine hydrobromide 114-49-8 0.0021
calcium gluconate 299-28-5 0.22
continued...
BOMAC SCOURBAN PLUS
ChemWatch Material Safety Data Sheet CHEMWATCH 4632-24
Issue Date: Fri 22-Apr-2005 CD 2005/2 Page 2 of 16
Section 3 - COMPOSITION / INFORMATION ON INGREDIENTS
magnesium sulfate, heptahydrate 10034-99-8 0.06
potassium chloride 7447-40-7 0.36
pectin 9000-69-5 0.71
glycine 56-40-6 2.09
Section 4 - FIRST AID MEASURES
SWALLOWED
鈥? For advice, contact a Poisons Information Centre or a doctor at once.
鈥? Urgent hospital treatment is likely to be needed.
鈥? If swallowed do NOT induce vomiting.
鈥? If vomiting occurs, lean patient forward or place on left side (head-down
position, if possible) to maintain open airway and prevent aspiration.
鈥? Observe the patient carefully.
鈥? Never give liquid to a person showing signs of being sleepy or with reduced
awareness; i.e. becoming unconscious.
鈥? Give water to rinse out mouth, then provide liquid slowly and as much as
casualty can comfortably drink.
鈥? Transport to hospital or doctor without delay.
EYE
If this product comes in contact with the eyes:
鈥? Wash out immediately with fresh running water.
鈥? Ensure complete irrigation of the eye by keeping eyelids apart and away from
eye and moving the eyelids by occasionally lifting the upper and lower lids.
鈥? If pain persists or recurs seek medical attention.
鈥? Removal of contact lenses after an eye injury should only be undertaken by
skilled personnel.
SKIN
If skin contact occurs:
鈥? Immediately remove all contaminated clothing, including footwear
鈥? Flush skin and hair with running water (and soap if available).
鈥? Seek medical attention in event of irritation.
INHALED
鈥? If fumes or combustion products are inhaled remove from contaminated area.
鈥? Other measures are usually unnecessary.
NOTES TO PHYSICIAN
Aminoglycoside antibiotics may be removed by haemodialysis or to a lesser extent
by peritoneal dialysis. Calcium salts given intravenously have been used to
counter neuromuscular blockade; the effectiveness of neostigmine has been
variable.
MARTINDALE: The Extra Pharmacopoeia, 29th Edition.
In cases of recent sulfonamide overdose the stomach should be emptied by
aspiration and lavage. If kidney function is adequate, a saline purgative, such
as sodium sulfate, 30 g in 250 ml water, may be given to promote peristalsis and
elimination of sulfonamide in the urine may be assisted by giving alkalies, such
as sodium bicarbonate and increasing fluid intake. Severe crystalluria may
require ureteric catheterisation and irrigation with warm 2.5% sodium
bicarbonate solution. Treatment should be continued until it can be assumed that
the sulfonamide has been eliminated. The majority of sulfonamides are
metabolised to acetylated derivatives which retain the toxicity of the parent
compound and thus may indicate more active removal when adverse effects are very
severe. Active measures may include forced diuresis, peritoneal dialysis and
charcoal haemoperfusion.
[Martindale: The Extra Pharmacopoeia, 28th Ed.].
continued...
BOMAC SCOURBAN PLUS
ChemWatch Material Safety Data Sheet CHEMWATCH 4632-24
Issue Date: Fri 22-Apr-2005 CD 2005/2 Page 3 of 16
Section 5 - FIRE FIGHTING MEASURES
EXTINGUISHING MEDIA
鈥? There is no restriction on the type of extinguisher which may be used.
Use extinguishing media suitable for surrounding area.
FIRE FIGHTING
鈥? Alert Fire Brigade and tell them location and nature of hazard.
鈥? Wear breathing apparatus plus protective gloves for fire only.
鈥? Prevent, by any means available, spillage from entering drains or water
courses.
鈥? Use fire fighting procedures suitable for surrounding area.
鈥? DO NOT approach containers suspected to be hot.
鈥? Cool fire exposed containers with water spray from a protected location.
鈥? If safe to do so, remove containers from path of fire.
鈥? Equipment should be thoroughly decontaminated after use.
FIRE/EXPLOSION HAZARD
鈥? Non combustible.
鈥? Not considered a significant fire risk, however containers may burn.
Decomposition may produce toxic fumes of, carbon dioxide (CO2), nitrogen oxides
(NOx), sulfur oxides (SOx), other pyrolysis products typical of burning organic
material.
May emit poisonous fumes.
May emit corrosive fumes.
FIRE INCOMPATIBILITY
Avoid contamination with oxidising agents i.e. nitrates, oxidising acids,
chlorine bleaches, pool chlorine etc. as ignition may result.
HAZCHEM
None
Personal Protective Equipment
PERSONAL PROTECTION EQUIPMENT
Gloves, boots (chemical resistant).
Section 6 - ACCIDENTAL RELEASE MEASURES
EMERGENCY PROCEDURES
MINOR SPILLS
鈥? Clean up all spills immediately.
鈥? Avoid breathing vapours and contact with skin and eyes.
鈥? Control personal contact by using protective equipment.
鈥? Contain and absorb spill with sand, earth, inert material or vermiculite.
鈥? Wipe up.
鈥? Place in a suitable labelled container for waste disposal.
MAJOR SPILLS
Moderate hazard.
鈥? Clear area of personnel and move upwind.
鈥? Alert Fire Brigade and tell them location and nature of hazard.
鈥? Wear breathing apparatus plus protective gloves.
鈥? Prevent, by any means available, spillage from entering drains or water
course.
鈥? Stop leak if safe to do so.
continued...
BOMAC SCOURBAN PLUS
ChemWatch Material Safety Data Sheet CHEMWATCH 4632-24
Issue Date: Fri 22-Apr-2005 CD 2005/2 Page 4 of 16
Section 6 - ACCIDENTAL RELEASE MEASURES
鈥? Contain spill with sand, earth or vermiculite.
鈥? Collect recoverable product into labelled containers for recycling.
鈥? Neutralise/decontaminate residue.
鈥? Collect solid residues and seal in labelled drums for disposal.
鈥? Wash area and prevent runoff into drains.
鈥? After clean up operations, decontaminate and launder all protective clothing
and equipment before storing and re-using.
鈥? If contamination of drains or waterways occurs, advise emergency services.
EMERGENCY RESPONSE PLANNING GUIDLINES (ERPG)
The maximum airborne concentration below which it is believed that nearly all
individuals could be exposed for up to one hour WITHOUT experiencing or developing
life-threatening health effects is:
kaolin 500 mg/m鲁
irreversible or other serious effects or symptoms which could
impair an individual's ability to take protective action is:
kaolin 100 mg/m鲁
other than mild, transient adverse effects
without perceiving a clearly defined odour is:
kaolin 6 mg/m鲁
The threshold concentration below which most people.
will experience no appreciable risk of health effects:
kaolin 5 mg/m鲁
American Industrial Hygiene Association (AIHA)
Personal Protective Equipment advice is contained in Section 8 of the MSDS.
Section 7 - HANDLING AND STORAGE
PROCEDURE FOR HANDLING
鈥? Avoid all personal contact, including inhalation.
鈥? Wear protective clothing when risk of exposure occurs.
鈥? Use in a well-ventilated area.
鈥? Avoid contact with moisture.
鈥? Avoid contact with incompatible materials.
鈥? When handling, DO NOT eat, drink or smoke.
鈥? Keep containers securely sealed when not in use.
鈥? Avoid physical damage to containers.
鈥? Always wash hands with soap and water after handling.
鈥? Work clothes should be laundered separately. Launder contaminated clothing
before re-use.
鈥? Use good occupational work practice.
鈥? Observe manufacturer's storing and handling recommendations.
鈥? Atmosphere should be regularly checked against established exposure standards
to ensure safe working conditions are maintained.
SUITABLE CONTAINER
鈥? Polyethylene or polypropylene container.
鈥? Packing as recommended by manufacturer
鈥? Check all containers are clearly labelled and free from leaks.
STORAGE INCOMPATIBILITY
Avoid reaction with oxidising agents.
continued...
BOMAC SCOURBAN PLUS
ChemWatch Material Safety Data Sheet CHEMWATCH 4632-24
Issue Date: Fri 22-Apr-2005 CD 2005/2 Page 5 of 16
Section 7 - HANDLING AND STORAGE
STORAGE REQUIREMENTS
鈥? Store in original containers.
鈥? Keep containers securely sealed.
鈥? Store in a cool, dry, well-ventilated area.
鈥? Store away from incompatible materials and foodstuff containers.
鈥? Protect containers against physical damage and check regularly for leaks.
鈥? Observe manufacturer's storing and handling recommendations.
Store below 30 degC.
Shelf Life: 2 years.
Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION
EXPOSURE CONTROLS
No data available for sulfamethazine as (CAS: 57-68-1)
No data available for kaolin as (CAS: 1332-58-7)
No data available for sulfaguanidine as (CAS: 57-67-0) / (CAS: 6190-55-2)
No data available for sulfadiazine as (CAS: 68-35-9)
No data available for sodium chloride as (CAS: 7647-14-5)
No data available for streptomycin sulfate as (CAS: 3810-74-0)
No data available for neomycin sulfate as (CAS: 1405-10-3)
No data available for hyoscine hydrobromide as (CAS: 114-49-8) / (CAS: 6533-68-2)
No data available for calcium gluconate as (CAS: 299-28-5)
No data available for magnesium sulfate, heptahydrate as (CAS: 10034-99-8)
No data available for potassium chloride as (CAS: 7447-40-7)
No data available for pectin as (CAS: 9000-69-5)
No data available for glycine as (CAS: 56-40-6)
Not available. Refer to individual constituents.
EXPOSURE STANDARDS FOR MIXTURE
"Worst Case" computer-aided prediction of spray/ mist or fume/ dust components
and concentration:
Composite Exposure Standard for Mixture (TWA) :2.7551 mg/m鲁.
Operations which produce a spray/mist or fume/dust, introduce particulates to
the breathing zone.
If the breathing zone concentration of ANY of the components listed below is
exceeded, "Worst Case" considerations deem the individual to be overexposed.
Component Breathing Zone ppm Breathing Zone mg/m鲁 Mixture Conc (%).
Component Breathing Zone Mixture Conc
(mg/m鲁) (%)
kaolin 0.6200 10.3
sulfamethazine 1.8607 31.0
hyoscine hydrobromide 0.0001 0.0
calcium gluconate 0.0132 0.2
pectin 0.0426 0.7
glycine 0.1254 2.1
potassium chloride 0.0216 0.4
sodium chloride 0.0678 1.1
magnesium sulfate, heptahydrate 0.0036 0.1
INGREDIENT DATA
For each of the following
SULFAMETHAZINE:
HYOSCINE HYDROBROMIDE:
CALCIUM GLUCONATE:
GLYCINE:
Dusts not otherwise classified, as inspirable dust;
continued...
BOMAC SCOURBAN PLUS
ChemWatch Material Safety Data Sheet CHEMWATCH 4632-24
Issue Date: Fri 22-Apr-2005 CD 2005/2 Page 6 of 16
Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION
ES TWA: 10 mg/m鲁.
Particulate (insoluble or poorly soluble *) Not Otherwise Specified (P.N.O.C)
TLV TWA: 10 mg/m鲁 Inhalable particulate
TLV TWA: 3 mg/m鲁 Respirable particulate
OEL-Sweden, United Kingdom: 10 mg/m鲁 total dust, 5 mg/m鲁 respirable dust
These "dusts" have little adverse effect on the lungs and do not produce toxic
effects or organic disease. Although there is no dust which does not evoke some
cellular response at sufficiently high concentrations, the cellular response
caused by P.N.O.C.s has the following characteristics:
路 the architecture of the air spaces remain intact,
路 scar tissue (collagen) is not synthesised to any degree,
路 tissue reaction is potentially reversible.
Extensive concentrations of P.N.O.C.s may:
路 seriously reduce visibility,
路 cause unpleasant deposits in the eyes, ears and nasal passages,
路 contribute to skin or mucous membrane injury by chemical or mechanical action,
per se, or by the rigorous skin cleansing procedures necessary for their
removal. [ACGIH]
This limit does not apply:
路 to brief exposures to higher concentrations
路 nor does it apply to those substances that may cause physiological impairment
at lower concentrations but for which a TLV has as yet to be determined.
This exposure standard applies to particles which
路 are insoluble or poorly soluble* in water or, preferably, in aqueous lung
fluid (if data is available) and
路 have a low toxicity (i.e.. are not cytotoxic, genotoxic, or otherwise
chemically reactive with lung tissue, and do not emit ionizing radiation, cause
immune sensitization, or cause toxic effects other than by inflammation or by a
mechanism of lung overload)
* Notice of intended change.
KAOLIN:
dust containing no asbestos and <1% crystalline silica
TLV TWA: 2 mg/m鲁 respirable dust A4
NOTE: This substance has been classified by the ACGIH as A4 NOT classifiable as
causing Cancer in humans.
ES TWA: 10 mg/m鲁 inspirable dust
OES TWA: 2 mg/m鲁 respirable dust
Kaolin dust appears to have fibrogenic potential even in the absence of
crystalline silica. Kaolinosis can exist as simple and complicated forms
with the latter often associated with respiratory symptoms. Crystalline
silica enhances the severity of the pneumoconiosis.
For each of the following
SULFAGUANIDINE:
STREPTOMYCIN SULFATE:
Airborne particulate or vapour must be kept to levels as low as is practicably
achievable given access to modern engineering controls and monitoring hardware.
Biologically active compounds may produce idiosyncratic effects which are
entirely unpredictable on the basis of literature searches and prior clinical
experience (both recent and past).
SULFADIAZINE:
Not available. Refer to individual constituents.
For each of the following
continued...
BOMAC SCOURBAN PLUS
ChemWatch Material Safety Data Sheet CHEMWATCH 4632-24
Issue Date: Fri 22-Apr-2005 CD 2005/2 Page 7 of 16
Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION
SODIUM CHLORIDE:
MAGNESIUM SULFATE, HEPTAHYDRATE:
POTASSIUM CHLORIDE:
Dusts not otherwise classified, as inspirable dust;
ES TWA: 10 mg/m鲁.
NEOMYCIN SULFATE:
No exposure limits set by NOHSC or ACGIH.
PECTIN:
Dusts not otherwise classified, as inspirable dust;
ES TWA: 10 mg/m鲁.
Particulate (insoluble or poorly soluble *) Not Otherwise Specified (P.N.O.C)
TLV TWA: 10 mg/m鲁 Inhalable particulate
TLV TWA: 3 mg/m鲁 Respirable particulate
OEL-Sweden, United Kingdom: 10 mg/m鲁 total dust, 5 mg/m鲁 respirable dust
These "dusts" have little adverse effect on the lungs and do not produce toxic
effects or organic disease. Although there is no dust which does not evoke some
cellular response at sufficiently high concentrations, the cellular response
caused by P.N.O.C.s has the following characteristics:
路 the architecture of the air spaces remain intact,
路 scar tissue (collagen) is not synthesised to any degree,
路 tissue reaction is potentially reversible.
Extensive concentrations of P.N.O.C.s may:
路 seriously reduce visibility,
路 cause unpleasant deposits in the eyes, ears and nasal passages,
路 contribute to skin or mucous membrane injury by chemical or mechanical action,
per se, or by the rigorous skin cleansing procedures necessary for their
removal. [ACGIH]
This limit does not apply:
路 to brief exposures to higher concentrations
路 nor does it apply to those substances that may cause physiological impairment
at lower concentrations but for which a TLV has as yet to be determined.
This exposure standard applies to particles which
路 are insoluble or poorly soluble* in water or, preferably, in aqueous lung
fluid (if data is available) and
路 have a low toxicity (i.e.. are not cytotoxic, genotoxic, or otherwise
chemically reactive with lung tissue, and do not emit ionizing radiation, cause
immune sensitization, or cause toxic effects other than by inflammation or by a
mechanism of lung overload)
* Notice of intended change.
PERSONAL PROTECTION
EYE
No special equipment for minor exposure i.e. when handling small quantities.
鈥? OTHERWISE:
鈥? Safety glasses with side shields.
鈥? Contact lenses pose a special hazard; soft lenses may absorb irritants and all
lenses concentrate them.
HANDS/FEET
No special equipment needed when handling small quantities.
OTHERWISE: Wear chemical protective gloves, eg. PVC.
continued...
BOMAC SCOURBAN PLUS
ChemWatch Material Safety Data Sheet CHEMWATCH 4632-24
Issue Date: Fri 22-Apr-2005 CD 2005/2 Page 8 of 16
Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION
OTHER
No special equipment needed when handling small quantities.
OTHERWISE:
鈥? Overalls.
鈥? Barrier cream.
鈥? Eyewash unit.
GLOVE SELECTION INDEX
Glove selection is based on a modified presentation of the:
"Forsberg Clothing Performance Index".
The effect(s) of the following substance(s) are taken into account in the
computer-generated selection:
Protective Material CPI *.
________________________________
________________________________
* CPI - Chemwatch Performance Index
A: Best Selection
B: Satisfactory; may degrade after 4 hours continuous immersion
C: Poor to Dangerous Choice for other than short term immersion
NOTE: As a series of factors will influence the actual performance of the glove,
a final selection must be based on detailed observation. -
* Where the glove is to be used on a short term, casual or infrequent basis,
factors such as "feel" or convenience (e.g. disposability), may dictate a choice
of gloves which might otherwise be unsuitable following long-term or frequent
use. A qualified practitioner should be consulted.
RESPIRATOR
Selection of the Class and Type of respirator will depend upon the level of
breathing zone contaminant and the chemical nature of the contaminant.
Protection Factors (defined as the ratio of contaminant outside and inside the
mask) may also be important.
Breathing Zone Maximum Protection Half-face Full-Face
Level ppm (volume) Factor Respirator Respirator
1000 10 -AUS P -
1000 50 - -AUS P
5000 50 Airline * -
5000 100 - -2 P
10000 100 - -3 P
100+ Airline**
* - Continuous Flow ** - Continuous-flow or positive pressure demand.
The local concentration of material, quantity and conditions of use determine
the type of personal protective equipment required. For further information
consult site specific CHEMWATCH data (if available), or your Occupational
Health and Safety Advisor.
ENGINEERING CONTROLS
General exhaust is adequate under normal operating conditions. Local exhaust
ventilation may be required in specific circumstances. If risk of overexposure
exists, wear approved respirator. Correct fit is essential to obtain adequate
protection. Provide adequate ventilation in warehouse or closed storage areas.
continued...
BOMAC SCOURBAN PLUS
ChemWatch Material Safety Data Sheet CHEMWATCH 4632-24
Issue Date: Fri 22-Apr-2005 CD 2005/2 Page 9 of 16
Section 9 - PHYSICAL AND CHEMICAL PROPERTIES
APPEARANCE
Pale pink suspension with a sweet characteristic odour.
PHYSICAL PROPERTIES
Liquid.
Molecular Weight: Not Applicable Boiling Range (掳C): Not Available
Melting Range (掳C): Not Available Specific Gravity (water=1): Not Available
Solubility in water (g/L): Not Available pH (as supplied): Not Available
pH (1% solution): Not Available Vapour Pressure (kPa): Not Available
Volatile Component (%vol): Not Available Evaporation Rate: Not Available
Relative Vapour Density (air=1): Not Available Flash Point (掳C): Not Applicable
Lower Explosive Limit (%): Not Applicable Upper Explosive Limit (%): Not Applicable
Autoignition Temp (掳C): Not Applicable Decomposition Temp (掳C): Not Available
State: Liquid
log Kow (Sangster 1997): 0.28
log Kow (Sangster 1997): -3.21
log Kow : -3.03- -1.7
Section 10 - CHEMICAL STABILITY AND REACTIVITY INFORMATION
CONDITIONS CONTRIBUTING TO INSTABILITY
鈥? Presence of incompatible materials.
鈥? Product is considered stable.
鈥? Hazardous polymerisation will not occur.
Section 11 - TOXICOLOGICAL INFORMATION
POTENTIAL HEALTH EFFECTS
ACUTE HEALTH EFFECTS
SWALLOWED
Considered an unlikely route of entry in commercial/industrial environments.
Sulfonamides and their derivatives may precipitate in kidney tubules causing
extensive damage. Haemolytic anaemia may also result from use or exposure.
Overdose may cause acidosis or hypoglycaemia with confusion and coma resulting.
Hypersensitivity reactions may occur in predisposed individuals including those
who have been sensitised by topical application. Deaths associated with
therapies based on sulfonamide appear to be a result of hypersensitivity
reaction, agranulocytosis, aplastic anaemia, other blood dyscrasias and renal
and hepatic failure. Doses of 2 to 5 gms have produced toxicity and fatalities.
Pathological findings include crystalluria, and necrotic or inflammatory lesions
of the heart, liver, kidneys, bone marrow or other organs. Sulfonamides may
damage the stem cell which acts as the precursor to components of the blood.
Loss of the stem cell may result in pancytopenia (a reduction in the number of
red and white blood cells and platelets) with a latency period corresponding to
the lifetime of the individual blood cells. Granulocytopenia (a reduction in
granular leukocytes) develops within days and thrombocytopenia (a disorder
involving platelets), within 1-2 weeks, whilst loss of erythrocytes (red blood
cells) need months to become clinically manifest. Aplastic anaemia develops due
to complete destruction of the stem cells. Sulfonamides cross the placental
continued...
BOMAC SCOURBAN PLUS
ChemWatch Material Safety Data Sheet CHEMWATCH 4632-24
Issue Date: Fri 22-Apr-2005 CD 2005/2 Page 10 of 16
Section 11 - TOXICOLOGICAL INFORMATION
barrier, are excreted in the breast milk and may produce adverse effects in the
foetus/ embryo and newborn including agranulocytosis, haemolytic anaemia,
jaundice and kernicterus.
So-called anticholinergic (parasympatholytic) agents (such as atropine,
belladonna alkaloids) block cholinergic effects produced by activation of both
muscarinic and nicotinic receptors. Clinical effects of these agents include
elevated blood pressure and temperature, erythema, delirium and mydriasis (all
of which are also produced by sympathomimetic agents) and in addition, silent
bowel sounds and dry skin.
EYE
Ophthalmic solutions containing sulfonamides are reported to produce local
irritation, reactive hyperaemia, burning and transient stinging, blurred vision
and temporary impairment of depth perception. Hypersensitivity reactions may
occur in predisposed individuals. Possible eye changes produced by phototoxic
agents such as the sulfonamides include kerato-conjunctivitis or corneal and
lens opacities.
The material may produce moderate eye irritation leading to inflammation.
Repeated or prolonged exposure to irritants may produce conjunctivitis.
Instillation or local application of anticholinergic agents in the eye may
produce a transient stinging sensation, dryness, redness and itchiness, dilation
of the pupils and cycloplegia with blurred vision. Pupillary reflex may not
fully recover for up to 3 days.
SKIN
The material may cause skin irritation after prolonged or repeated exposure and
may produce a contact dermatitis (nonallergic). This form of dermatitis is often
characterised by skin redness (erythema) and swelling epidermis. Histologically
there may be intercellular oedema of the spongy layer (spongiosis) and
intracellular oedema of the epidermis.
Entry into the blood-stream, through, for example, cuts, abrasions or lesions,
may produce systemic injury with harmful effects. Examine the skin prior to the
use of the material and ensure that any external damage is suitably protected.
INHALED
Not normally a hazard due to non-volatile nature of product.
The material is not thought to produce either adverse health effects or
irritation of the respiratory tract following inhalation (as classified by EC
Directives using animal models). Nevertheless, adverse systemic effects have
been produced following exposure of animals by at least one other route and good
hygiene practice requires that exposure be kept to a minimum and that suitable
control measures be used in an occupational setting.
CHRONIC HEALTH EFFECTS
Principal routes of exposure are by accidental skin and eye contact and by
inhalation of vapours especially at higher temperatures. Repeated ingestion of
sulfonamides used for therapeutic purposes has caused nausea, vomiting,
abdominal pain, diarrhoea, anorexia, stomatitis, impaired folic acid absorption,
exacerbation of porphyria, acidosis, liver injury with jaundice and
hypoprothrombinemia, and pancreatitis. Hepatitis has been reported and may be
fatal. Renal effects are often prominent and may include crystalluria,
haematuria, proteinuria, pain and frequent urination, necrosis of the tubules,
nephritic syndrome, and toxic necrosis with oliguria or anuria with azotemia.
Neurologic effects include headache, drowsiness, insomnia, vertigo, tinnitus,
hearing loss, mental depression, hallucinations, ataxia, muscular paralysis,
peripheral neuropathy, transient lesions of the posterior spinal column,
transverse myelitis, convulsions and unconsciousness. Haematological effects
include eosinophilia, thrombocytopenia, leukopenia, neutropenia,
agranulocytosis, pancytopenia, megoblastic anaemia, Heinz body anaemia and
aplastic anaemia; petechiae and purpura may result. Acute haemolytic anaemia may
continued...
BOMAC SCOURBAN PLUS
ChemWatch Material Safety Data Sheet CHEMWATCH 4632-24
Issue Date: Fri 22-Apr-2005 CD 2005/2 Page 11 of 16
Section 11 - TOXICOLOGICAL INFORMATION
also result (possibly as a result of hypersensitivity reactions) with people of
African descent apparently more susceptible than Europeans - glucose-6-phosphate
deficiency also appears to be a factor. Methaemoglobinaemia,
sulfhaemoglobinaemia and cyanosis may also occur. Ocular effects may include
acute transient myopia, keratitis and conjunctivitis with inflammation and
chemosis accompanied by swelling of the lids and in more severe cases,
photophobia. Cross-sensitivity amongst the sulfonamides is common and allergic
reaction may occur following systemic use or topical application. Sensitisation
may produce generalised skin eruptions, urticaria and pruritus. Stevens-Johnson
syndrome; a severe form of erythema multiforme associated with wide-spread
lesions of the skin, mucous membranes and which may be fatal in about 25% of
cases, has occurred in patients treated with sulfonamides. This syndrome may
produce conjunctival and corneal scarring, serum sickness, periorbital oedema,
angioedema, arthritis, arthralgia, allergic myocarditis, decreased pulmonary
function and eosinophilic pneumonia. Other effects of long-term therapy include
fever, chills, alopecia, vasculitis, lupus erythematous, oligospermia,
infertility, hypothyroidism and on occasion, goiter and diuresis. More severe
responses to treatment include irreversible neuromuscular and central nervous
system changes and fibrosing alveolitis. During sulfonamide treatment, direct
exposure to sunlight should be avoided as photosensitisation dermatitis may
develop. This form of phototoxic dermatitis may be contrasted to photoallergic
dermatitis produced by specific sensitising agents through immunological
intervention. Phototoxic reactions have been described following contact,
ingestion or injection of causal agents. The chemical may reach the skin by the
circulatory system following ingestion or following parenteral administration.
The actual skin changes vary with the agent and circumstances of the exposure.
Swelling and redness (erythema) frequently occur, and blistering may also
result; increased skin temperature and pruritus may follow. This is analagous to
irritant contact dermatitis and occurs immediately following contact.
Hyperpigmentation may also follow the reaction. Photodermatitis of this type
requires activation of a chemical substance on the skin surface by UV radiation
(290 to 490 nm wavelength) for its clinical expression. In all cases,
inflammation develops on the body surfaces normally exposed to sunlight (dorsal
hands, arms, neck, face), provided that the responsible photosensitiser also
contacts the anatomic areas. Covered skin, the eyelids, submental chin and upper
ears covered by hair, are characteristically spared. Phototoxic reactions,
analogous to irritant contact dermatitis, are typically accompanied by immediate
burning, stinging or "smarting" of the skin shortly following sun exposure, and
clinical inflammation appears more like an acute sunburn than an eczematous
dermatitis. Photoallergic dermatitis may result from contact with the material;
this is characterised by an increased reactivity of the skin to ultra- violet
(UV) and/or visible radiation produced by a chemical agent on an immunological
basis and occurs after a latent period of days or months. This type of response
can be elicited only in individuals who have been previously allergically
sensitised to the chemical agent and appropriate radiation. Photoallergic
dermatitis is relatively rare (certainly more so than phototoxic dermatitis
produced by non-immunological principals) and presents, clinically, as an
eczematous dermatitis in sun-exposed areas (distinguishing it from phototoxic
dermatitis which is analogous to contact irritant dermatitis and produces
swelling, redness and even blistering); photoallergic dermatitis may eventually
spread to areas covered by clothes. Lichenification (thickening with increased
skin markings) and chronic pigmentary changes may also develop. Photoallergic
reactions may sometimes be followed by a persistent state of light reactivity
(persistent light reactor) where clinical dermatitis recurs following exposure
to sunlight alone, in the absence of the original initiating chemical. Studies
in rats have shown that long-term administration of sulfonamides may produce
thyroid malignancies; rats, however, appear to be more susceptible to the
goiterogenic effects of sulfonamides than do other animal species. Sulfonamides
may cause kernicterus in the neonate and their use is not recommended during
pregnancy. Studies in rats and mice given high oral doses have shown that
continued...
BOMAC SCOURBAN PLUS
ChemWatch Material Safety Data Sheet CHEMWATCH 4632-24
Issue Date: Fri 22-Apr-2005 CD 2005/2 Page 12 of 16
Section 11 - TOXICOLOGICAL INFORMATION
certain sulfonamides cause a significant incidence of cleft palate and other
bony abnormalities in the foetus. As with any chemical product, contact with
unprotected bare skin; inhalation of vapour, mist or dust in work place
atmosphere; or ingestion in any form, should be avoided by observing good
occupational work practice.
TOXICITY AND IRRITATION
MATERIAL CARCINOGEN SENSITISER SKIN MUTAGEN REPROTOXIN
______________________________ ____________ __________ __________ __________ __________
Bomac Scourban Plus
sulfamethazine
kaolin Yes
sulfaguanidine
sulfadiazine
sodium chloride
streptomycin sulfate Yes
neomycin sulfate Yes
hyoscine hydrobromide
calcium gluconate
magnesium sulfate,
heptahydrate
potassium chloride
pectin
glycine
CARCINOGEN
ACGIH: kaolin: A4
REPROTOXIN
Californian Proposition 65 - Reproductive Toxicity:
TYPE: streptomycin sulfate: developmental DATE LISTED: January 1, 1991
REPROTOXIN
Californian Proposition 65 - Reproductive Toxicity:
TYPE: neomycin sulfate: developmental DATE LISTED: October 1, 1992
Not available. Refer to individual constituents.
unless otherwise specified data extracted from RTECS - Register of Toxic Effects
of Chemical Substances
SULFAMETHAZINE:
TOXICITY IRRITATION
Subcutaneous (rat) LD50: 2000 mg/kg Nil reported
Oral (mouse) LD50: 50000 mg/kg
Intraperitoneal (mouse) LD50: 1060 mg/kg
Subcutaneous (mouse) LD50: 1440 mg/kg
Intravenous (mouse) LD50: 1776 mg/kg
Intravenous (rabbit) LD50: 2450 mg/kg
Somnolence, dyspnea recorded.
The substance is classified by IARC as Group 3:
NOT classifiable as to its carcinogenicity to humans.
Evidence of carcinogenicity may be inadequate or limited in animal testing.
KAOLIN:
~OTHER
No significant acute toxicological data identified in literature search.
SULFAGUANIDINE:
No significant acute toxicological data identified in literature search.
SULFADIAZINE:
continued...
BOMAC SCOURBAN PLUS
ChemWatch Material Safety Data Sheet CHEMWATCH 4632-24
Issue Date: Fri 22-Apr-2005 CD 2005/2 Page 13 of 16
Section 11 - TOXICOLOGICAL INFORMATION
Not available. Refer to individual constituents.
SODIUM CHLORIDE:
TOXICITY IRRITATION
Oral (rat) LD50: 3000 mg/kg Skin (rabbit): 500 mg/24h - mild
Oral (human) TDLo: 12357 mg/kg/23d Eye (rabbit): 10 mg - moderate
Oral Lowest Toxic Dose (Human): 8.2 mg/kg Eye
(rabbit):100 mg/24h - moderate
STREPTOMYCIN SULFATE:
TOXICITY IRRITATION
Subcutaneous (mouse) LD50: 500 mg/kg Nil reported
Intravenous (mouse) LD50: 90.2 mg/kg
Oral (hamster) LD50: 400 mg/kg
Bacterial mutagen
Reproductive effector in rats
NEOMYCIN SULFATE:
TOXICITY IRRITATION
Oral (woman) TDLo: 12600 mg/kg/7d Skin (human): 6 mg/3d - I - mild
HYOSCINE HYDROBROMIDE:
TOXICITY IRRITATION
Oral (rat) LD50: 1270 mg/kg Nil reported
Subcutaneous (rat) LD50: 3800 mg/kg
CALCIUM GLUCONATE:
No significant acute toxicological data identified in literature search.
MAGNESIUM SULFATE, HEPTAHYDRATE:
TOXICITY IRRITATION
Oral (man) TDLo: 183 mg/kg/4h-I Nil reported
POTASSIUM CHLORIDE:
TOXICITY IRRITATION
Oral (man) LDLo: 20 mg/kg Eye (rabbit): 500 mg/24h - mild
Oral (woman) TDLo: 60 mg/kg
Oral (rat) LD50: 2600 mg/kg
PECTIN:
~TOXICITY FIGURE
Subcutaneous~rat~LD50~6400~mg/kg
~OTHER
Nil reported
GLYCINE:
TOXICITY IRRITATION
Oral (rat) LD50: 7930 mg/kg Nil reported
Section 12 - ECOLOGICAL INFORMATION
DO NOT discharge into sewer or waterways.
Refer to data for ingredients, which follows:
SULFAMETHAZINE:
Hazardous Air Pollutant: No
log Kow (Sangster 1997): 0.28
KAOLIN:
continued...
BOMAC SCOURBAN PLUS
ChemWatch Material Safety Data Sheet CHEMWATCH 4632-24
Issue Date: Fri 22-Apr-2005 CD 2005/2 Page 14 of 16
Section 12 - ECOLOGICAL INFORMATION
SULFAGUANIDINE:
No data for sulfaguanidine.
SULFADIAZINE:
SODIUM CHLORIDE:
TLm 96 > 1000 ppm
STREPTOMYCIN SULFATE:
No data for streptomycin sulfate.
NEOMYCIN SULFATE:
No data for neomycin sulfate.
HYOSCINE HYDROBROMIDE:
No data for hyoscine hydrobromide.
CALCIUM GLUCONATE:
No data for calcium gluconate.
MAGNESIUM SULFATE, HEPTAHYDRATE:
No data for magnesium sulfate, heptahydrate.
POTASSIUM CHLORIDE:
No data
PECTIN:
GLYCINE:
Hazardous Air Pollutant: No
log Pow (Verschueren 1983): 1.78235294
Hazardous Air Pollutant: No
log Kow (Sangster 1997): -3.21
log Kow : -3.03- -1.7
BOD 5 if unstated: 0.385-0.548,86%
COD : 0.46
ThOD : 0.72,0.64
Degradation Biological: sig
Section 13 - DISPOSAL CONSIDERATIONS
鈥? Recycle wherever possible.
鈥? Consult manufacturer for recycling options or consult local or regional waste
management authority for disposal if no suitable treatment or disposal facility
can be identified.
鈥? Dispose of by: Burial in a licenced land-fill or Incineration in a licenced
apparatus (after admixture with suitable combustible material)
鈥? Decontaminate empty containers. Observe all label safeguards until containers
are cleaned and destroyed.
continued...
BOMAC SCOURBAN PLUS
ChemWatch Material Safety Data Sheet CHEMWATCH 4632-24
Issue Date: Fri 22-Apr-2005 CD 2005/2 Page 15 of 16
Section 13 - DISPOSAL CONSIDERATIONS
Puncture containers to prevent re-use and bury at an authorised landfill.
Section 14 - TRANSPORTATION INFORMATION
Shipping Name:
None
Dangerous Goods Class: None, None
UN/NA Number: None
ADR Number: None
Packing Group: None
Labels Required:
Additional Shipping Information:
International Transport Regulations:
IMO: None
HAZCHEM
None
Section 15 - REGULATORY INFORMATION
POISONS SCHEDULE
None
REGULATIONS
sulfamethazine (CAS: 57-68-1) is found on the following regulatory lists:
Australian Inventory of Chemical Substances (AICS)
Australian Poisons Schedule
kaolin (CAS: 1332-58-7) is found on the following regulatory lists:
Australia High Volume Industrial Chemical List (HVICL)
Australian Inventory of Chemical Substances (AICS)
sulfaguanidine (CAS: 57-67-0) is found on the following regulatory lists:
Australian Inventory of Chemical Substances (AICS)
Australian Poisons Schedule
sulfaguanidine (CAS: 6190-55-2) is found on the following regulatory lists:
Australian Inventory of Chemical Substances (AICS)
sulfadiazine (CAS: 68-35-9) is found on the following regulatory lists:
Australian Inventory of Chemical Substances (AICS)
Australian Poisons Schedule
sodium chloride (CAS: 7647-14-5) is found on the following regulatory lists:
Australian Inventory of Chemical Substances (AICS)
streptomycin sulfate (CAS: 3810-74-0) is found on the following regulatory
lists:
Australian Inventory of Chemical Substances (AICS)
Australian Poisons Schedule
neomycin sulfate (CAS: 1405-10-3) is found on the following regulatory lists:
Australian Inventory of Chemical Substances (AICS)
Australian Poisons Schedule
hyoscine hydrobromide (CAS: 114-49-8) is found on the following regulatory
lists:
continued...
BOMAC SCOURBAN PLUS
ChemWatch Material Safety Data Sheet CHEMWATCH 4632-24
Issue Date: Fri 22-Apr-2005 CD 2005/2 Page 16 of 16
Section 15 - REGULATORY INFORMATION
Australian Inventory of Chemical Substances (AICS)
Australian Poisons Schedule
hyoscine hydrobromide (CAS: 6533-68-2) is found on the following regulatory
lists:
Australian Inventory of Chemical Substances (AICS)
calcium gluconate (CAS: 299-28-5) is found on the following regulatory lists:
Australian Inventory of Chemical Substances (AICS)
magnesium sulfate, heptahydrate (CAS: 10034-99-8) is found on the following
regulatory lists:
Australian Inventory of Chemical Substances (AICS)
potassium chloride (CAS: 7447-40-7) is found on the following regulatory lists:
Australia High Volume Industrial Chemical List (HVICL)
Australian Inventory of Chemical Substances (AICS)
pectin (CAS: 9000-69-5) is found on the following regulatory lists:
Australian Inventory of Chemical Substances (AICS)
glycine (CAS: 56-40-6) is found on the following regulatory lists:
Australian Inventory of Chemical Substances (AICS)
Section 16 - OTHER INFORMATION
This document is copyright. Apart from any fair dealing for the purposes of
private study, research, review or criticism, as permitted under the Copyright
Act, no part may be reproduced by any process without written permission from
CHEMWATCH. TEL (+61 3) 9572 4700.
Issue Date: Fri 22-Apr-2005
Print Date: Wed 15-Jun-2005
|